DMG-pSar25
Based on 1 Customer Validation
DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99%
- No. CAS: 2936622-30-7
- Peso molecular:2416.93
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
DMG-pSar25 (50 ng firefly luciferase mRNA per well; 18 h) enhances mRNA delivery efficiency in ALC-0315 (HY-138300)-based LNPs in C2C12 and Hep3B cells compared to ALC-0159 PEG controls, while maintaining comparable cell viability[1].
DMG-pSar25 (50 ng firefly luciferase mRNA per well; 18 h) maintains mRNA delivery efficiency in SM-102 (HY-134541)-based LNPs in C2C12 and Hep3B cells compared to DMG-PEG2000 controls, while maintaining comparable cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:0.06 µg mRNA
-
Administration:i.m.; single administration
-
Result:Produced greater than 5-fold higher total flux (luminescence intensity) than ALC-0315-based LNPs formulated with ALC-0159 PEG lipid.
Resulted in significantly higher hEPO levels in muscle (P = 0.008) compared to ALC-0315-based LNPs with ALC-0159 PEG lipid; hEPO levels in blood were similar between the two groups.
Showed comparable total flux and hEPO levels (blood and muscle) to SM-102-based LNPs formulated with DMG-PEG2000.
Exhibited cytokine/chemokine profiles largely similar to PEG-formulated LNPs, with SM-102-based DMG-pSar25 LNPs showing significantly higher levels of G-CSF (P = 0.005), IL-6 (P = 0.0003), CXCL10 (P = 0.04), CXCL1 (P = 0.0008), M-CSF (P = 0.01), CXCL9 (P = 0.04), and CCL4 (P = 0.02) compared to SM-102-based DMG-PEG2000 LNPs; ALC-0315-based DMG-pSar25 LNPs showing significantly higher levels of IFNγ (P = 0.02), IL-6 (P = 0.008), IL-4 (P = 0.04), and IL-5 (P = 0.02), and significantly lower IL-2 (P = 0.04) compared to ALC-0315-based ALC-0159 LNPs.
Did not induce anti-PEG IgG production upon repeat administration, whereas repeat administration of PEG-formulated LNPs did (P = 0.04).
Did not cause significant elevation of plasma aspartate transaminase (AST) and alanine transaminase (ALT) levels compared to PBS-treated mice.
Chemical Information
-
No. CAS 2936622-30-7
-
Appearance Solid
-
Peso molecular 2416.93
-
Color White to off-white
-
SMILES
CN(C(CCC(OC[C@]([H])(OC(CCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCC)=O)=O)=O)C(CNCC)=O.[n]
-
Structure Classification
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
Ethanol : ≥ 50 mg/mL (20.69 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 0.4137 mL | 2.0687 mL | 4.1375 mL | 10.3437 mL |
| 5 mM | 0.0827 mL | 0.4137 mL | 0.8275 mL | 2.0687 mL | |
| 10 mM | 0.0414 mL | 0.2069 mL | 0.4137 mL | 1.0344 mL | |
| 15 mM | 0.0276 mL | 0.1379 mL | 0.2758 mL | 0.6896 mL | |
| 20 mM | 0.0207 mL | 0.1034 mL | 0.2069 mL | 0.5172 mL |
DMG-pSar25 Related Classifications
HY-N16040 Related Classifications
Powered by Bioz